The PRISM individual-patient-data meta-analysis combined the ProCESS, ARISE and ProMISe trials to examine whether early goal-directed therapy (EGDT) improved outcomes in adults with septic shock compared with contemporary usual care. These large multicentre trials had already failed to show a benefit for the original Rivers-style EGDT approach, but the pooled analysis allowed investigators to assess the evidence at patient level and explore whether particular subgroups benefited. The combined results found no meaningful mortality advantage for EGDT over usual care and no convincing interaction suggesting that a specific patient subgroup consistently derived benefit. The paper is important because it places the modern sepsis trials in context: patients in contemporary emergency and ICU systems already receive rapid antibiotics, fluids, vasopressors and frequent reassessment, making a rigid protocol less likely to add value. The lesson for practice is not to abandon structured resuscitation, but to focus on timely care and physiologic targets while allowing clinicians to individualise therapy. The meta-analysis also illustrates how evidence can change when a single-centre protocol is tested across diverse health systems. For intensivists, it supports a flexible resuscitation strategy rather than automatic pursuit of every component of a historic EGDT algorithm.